Int J Angiol
DOI: 10.1055/s-0039-1679873
Reply of Letter to the Editor
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Author's Rebuttal

Frank Manetta
1  Department of Cardiovascular and Thoracic Surgery at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, New York
› Author Affiliations
Further Information

Publication History

Publication Date:
02 March 2019 (online)

Comment on: Indications for Thoracic Endovascular Aortic Repair (TEVAR): A Brief Review by Frank Manetta, MD, Joshua Newman, MS, Allan Mattia, MD. Int J Angiol 2018; 28:177–184

We would like to thank Mr. Bohan for his comment as well as acknowledge the significance of the Bolton Relay device with Plus Delivery System.

As mentioned, the device has been demonstrated safe for utilization both with penetrating atherosclerotic ulcers (PAU) and descending thoracic aortic aneurysms (TAA) in the Bolton Relay Thoracic Aortic Endovascular Pivotal Trial demonstrating 5-year freedom from all-cause mortality as high as 57% compared with 50.2% (p = 0.289) in the surgical arm. With the improved Plus Delivery System, the Bolton Relay device is a considerable option for endovascular management of both TAAs and PAUs and may be considered for additional aortic pathologies as well. As with all current endovascular devices, long-term efficacy remains to be demonstrated and continued research will help to elucidate the longevity of endovascular interventions. Thank you.